PRA looks to bring child-friendly solutions to pediatric clinical trials

By Melissa Fassbender contact

- Last updated on GMT

Approximately 70% of all medicines used for children are used off label. (Image: iStock/acobchuk)
Approximately 70% of all medicines used for children are used off label. (Image: iStock/acobchuk)
PRA Health Sciences has launched a new Center for Pediatric Clinical Development and a correlating site network to facilitate patient recruitment and improved engagement and retention. 

We launched the center to act as a central repository of all pediatric knowledge for both internal and external stakeholders​,” Mark Sorrentino, MD, MS, VP at The Center for Pediatric Clinical Development.

“Given the current regulatory environment requiring studies earlier in the clinical development process, we feel our clients are looking for innovation in this space​,” he said.

In addition, Sorrentino explained about 70% of all medicines used for children are used off label and haven’t been through​ a randomized trial. “We hope that our ability to bring innovative solutions to these trials will help bring properly studied medicines to this vulnerable population​,” he added.

The center enables the Raleigh, North Carolina-based contract research organization (CRO) to organize its pediatric​ expertise across functional areas into a “single global resource​,” added Sorrentino.

Our pediatric collaboration team will be able to review protocols and provide feedback and ideas to teams from proposal phase to end-of-trial activities​,” he explained.

Next steps include forming a global pediatric site network.

In addition, we are partnering with external companies who innovate using technology platforms and other child friendly concepts to make participation in a clinical trial a more educated and pleasant experience​,” said Sorrentino.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers